Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Research Regulatory News (EDEN)

Share Price Information for Eden Research (EDEN)

Share Price is delayed by 15 minutes
Get Live Data
3.20    0.00 (0.00%)
Bid:
3.10
Ask:
3.30
Spread: 0.20 (6.452%)
Market Cap: £25.71m
EDEN Live PriceLast checked at - London Stock Exchange

Intraday Eden Research Share Chart

EU Product Authorisation - Cedroz

20 Feb 2019 07:00

RNS Number : 5325Q
Eden Research plc
20 February 2019
 

 

 

 

20 February 2019

 

Eden Research plc

 

("Eden" or "Company")

 

EU Product Authorisation - Cedroz

 

Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, is pleased to announce that its commercial partner, Eastman Chemical Company ("Eastman"), has received authorisation for Eden's nematicide formulation, marketed as Cedroz by Eastman, from the Regulatory Affairs Directorate in Malta. Malta is acting as the zonal rapporteur Member State for the Southern EU agricultural zone and on behalf of a number of EU countries for indoor uses.

Cedroz is an innovative and natural solution designed to fight nematodes, a species that is known to cause severe damage to crops globally for both open field and greenhouse growers, resulting in yield losses and increasing farmers costs. Malta has authorised the use of Cedroz on a wide range of crops, including cucumbers, courgettes, melons, aubergine, peppers, tomatoes and strawberries. 

In line with consumer demand and a regulatory push for "safer" products, Cedroz is an attractive alternative for farmers looking to fight nematodes in an environmentally friendly way. Unlike many other products, Cedroz will have zero residues and a zero-day pre-harvest interval, thereby allowing applications right up to harvest, if required. 

Following the authorisation by Malta, the concerned Member States ("cMS") must grant their individual approvals for the sale and use of Cedroz within their jurisdictions. The pending approvals will cover Spain and Italy, for outdoor uses and will also cover France, Belgium, the Netherlands and the United Kingdom, as well as Spain and Italy, for professional greenhouse uses. Once approved, Cedroz will be the first of Eden's formulations to be sold and used in the United Kingdom, where the company is headquartered.

Sean Smith, Chief Executive Officer of Eden, said: "Following Eden's initial investment in the formulation of this important product , Eastman has invested significant resource over the past three years in the further development of Cedroz, and it is pleasing to see our collective efforts coming to fruition.

"Traditional crop protection products are increasingly coming under threat from global regulatory pressures , based upon the potential impact these products may have on the environment. There is significant demand for biopesticides as an alternative measure, due to its safe nature and the absence of pesticide residue and we are looking forward to working with Eastman to capitalise on this growing demand and helping them to launch the product in a number of new territories, including the UK.

"The UK imported £5.4bn worth of its fruit and vegetables in the first six months of 2018 and has a heavy reliance on the EU for produce. Almost a fifth (19%) of imports come from Spain, and 11% from the Netherlands. Within the UK, the application of Cedroz would help to increase the yield of home-grown products, such as cucumbers and tomatoes, for every day produce."

Guy Van Den Bossche, General Manager Crop Protection at Eastman, said: "This authorisation by Malta is a great achievement for the commercial development of Cedroz. We gained strong interest in the product from farmers, following successful trials, and are confident that Cedroz will now prove itself in field and greenhouse both as a standalone solution to the problem of root-knot nematodes and as part of integrated pest management programs for the approved geographies and crops."

 

For further information contact:

Eden Research plc

www.edenresearch.com

Sean Smith

Alex Abrey

01285 359 555

Shore Capital (Nomad)

020 7408 4090

Stephane Auton / Patrick Castle

Powerscourt (Financial PR)

020 7250 1446

Nick Dibden

Jana Tsiligiannis

eden@powerscourt-group.com

 

Notes:

 

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

 

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

 

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

 

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

 

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £13m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements. 

 

In May 2013, the three actives that comprise Eden's first commercial product, Mevalone, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

 

Mevalone has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus, Albania and Portugal.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

 

For more information about Eden, please visit: www.edenresearch.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCTLMRTMBJBBPL
Date   Source Headline
2nd Nov 20207:00 amRNSEden partners with M H Poskitt
13th Oct 20207:00 amRNSChange of Registered Office
29th Sep 20207:00 amRNSHalf-year Report
17th Sep 20207:00 amRNSNew authorisations for Cedroz™ and Mevalone®
15th Sep 20207:00 amRNSKey patent granted for Eden’s Sustaine technology
1st Sep 20207:00 amRNSRegulatory approval for Cedroz™ in Spain
25th Aug 20207:00 amRNSNew authorisation for bio-fungicide in Australia
5th Aug 20207:00 amRNSNew authorisation for Cedroz™ in Greece
10th Jul 20207:00 amRNSAppointment of Global Head of Biology and Dev
1st Jul 20207:00 amRNSNew office and laboratory in Oxfordshire
25th Jun 20207:00 amRNSPatents granted in the United States
24th Jun 202012:20 pmRNSResult of AGM
29th May 20207:58 amRNSIssuing of Annual Report & Notice of AGM
27th May 20207:00 amRNSUpdate on Bayer Animal Health Agreement
20th May 20207:00 amRNSNew authorisations for Cedroz and Mevalone
7th May 20207:00 amRNSFinancial Results for Year Ended 31 December 2019
6th May 20205:09 pmRNSNotice of Results
15th Apr 20207:00 amRNSAppointment of Director of Regulatory Affairs
8th Apr 202010:03 amRNSOrganic farming certification in Italy and Spain
24th Mar 20208:20 amRNSHolding(s) in Company
20th Mar 20205:33 pmRNSHolding(s) in Company
20th Mar 20203:37 pmRNSHolding(s) in Company
20th Mar 202010:33 amRNSHolding(s) in Company
18th Mar 202011:18 amRNSResults of General Meeting & Open Offer
5th Mar 20207:00 amRNSDirector/PDMR Shareholding
28th Feb 20201:35 pmRNSPlacing, Subscription & Open Offer
20th Jan 20207:00 amRNSAppointment of Hawthorn Advisors
14th Jan 20207:00 amRNSYear-end trading update
8th Jan 20207:00 amRNSAgreement with Corteva Agriscience
7th Jan 20207:00 amRNSRegulatory Approval- Organic Production Regulation
23rd Dec 20197:00 amRNSAgreement with Sipcam Oxon in Portugal and Benelux
19th Dec 20197:00 amRNSApproval of Cedroz in Mexico
17th Dec 20197:00 amRNSDistribution Agreement with SumiAgro Europe
16th Oct 201912:48 pmRNSDirector/PDMR Shareholding
16th Oct 20197:00 amRNSCedroz Approval
18th Sep 20197:00 amRNSHalf Yearly Report
29th Jul 20197:00 amRNSGrant of 'Emergency use' authorisation
8th Jul 20197:00 amRNSChange of Adviser
28th Jun 20192:42 pmRNSReplacement - Grant of Awards
28th Jun 201911:43 amRNSGrant of Awards under Long-Term Incentive Plan
28th Jun 20197:00 amRNSDirector/PDMR Shareholding
12th Jun 20197:00 amRNSAppointment of Commercial Director
15th May 20198:10 amRNSResult of AGM
14th May 20197:00 amRNSAGM Statement
9th May 20197:00 amRNSSales of Cedroz commence in Italy
26th Apr 20197:00 amRNSItaly grants "emergency use" Cedroz authorisation
16th Apr 201912:43 pmRNSDirector/PDMR Shareholding
16th Apr 20197:00 amRNSIssuing of Annual Report & Notice of AGM
2nd Apr 20197:00 amRNSFinancial Results for Year Ended 31 December 2018
5th Mar 20192:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.